Robb Gary Charles sold $1.2M of CORT (indirect holdings)

Robb Gary Charles (Chief Business Officer) sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $116.26 ($1.16M total) on 2026-08-17.

Original reporting
SEC EDGAR · Robb Gary Charles
Published Aug 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but there is no new operational or financial information in the text.

02

Market read

A CBO insider open-market sale of $1.16M worth of CORT shares was disclosed, with no 10b5-1 plan cited.

03

What to watch

The filing notes the sale was open-market and indicates no pre-arranged 10b5-1 plan, which can increase headline sensitivity even if the economic signal is weak.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

This is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported via EDGAR.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics disclosed an insider open-market sale of 10,000 shares by CBO Robb Gary Charles at $116.2572 on 2026-08-17.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but does not include new company performance, guidance, or regulatory/contract developments.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity needs and does not necessarily signal reduced confidence, especially without any accompanying negative company-specific news.

Key entities

  • CORCEPT THERAPEUTICS INC

    Company that filed the Form 4 insider transaction disclosure.

  • Robb Gary Charles

    Chief Business Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.